Nu-Med Plus, Inc.
NUMD · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 1.69 | -0.91 | 0.61 |
| FCF Yield | -0.50% | 0.00% | 0.00% | -0.13% |
| EV / EBITDA | 0.00 | -387.36 | 0.00 | 0.00 |
| Quality | ||||
| ROIC | 0.00% | 7.10% | 13.85% | 8.07% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 5.06 | -0.01 | – | 0.16 |
| Growth | ||||
| Revenue 3-Year CAGR | 84,243.27% | 84,243.27% | 84,243.27% | 84,243.27% |
| Free Cash Flow Growth | -8,380.38% | 0.00% | 100.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -9.52 | 0.00 | 0.00 |
| Interest Coverage | 0.00 | -8.36 | -15.17 | -7.37 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -32,925.00 |